干细胞治疗肝脏疾病研究进展*

doi:10.3969/j.issn.1672-5069.2018.01.042

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (1): 145-148.doi: 10.3969/j.issn.1672-5069.2018.01.042

干细胞治疗肝脏疾病研究进展^*

李珊珊, 洪丰综述, 陈煜审校

100069 北京市首都医科大学附属北京佑安医院人工肝中心（李珊珊,陈煜）;
山东省济宁医学院附属医院（洪丰）

收稿日期:2017-04-12 出版日期:2018-01-10 发布日期:2018-01-29
通讯作者: 陈煜,E-mail：chybeyond@163.com
作者简介:李珊珊女,28岁,博士研究生,主治医师。主要从事肝衰竭的基础与临床研究。
基金资助:
*国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”（编号：2017ZX10203201-005）; 北京市医院管理局“登峰”人才培养计划基金资助项目（编号： DFL20151601）; 北京市卫生系统高技术人才培养项目基金（编号：2013-3-071）; “起点未来”医学发展项目（编号：Future-101）

Stem cell therapy in liver diseases

Li Shanshan, Hong Feng, Chen Yu

Centre for Liver Disease Study and Artificial Liver Therapy Center,Youan Hospital,Capital Medical University,Beijing 100069,China

Received:2017-04-12 Online:2018-01-10 Published:2018-01-29

摘要/Abstract

摘要： 干细胞是一类具有自我更新、增殖和多向分化潜能的细胞群体,作为最有潜力的种子细胞来源,近年来受到国内外广泛的关注,已有大量干细胞应用于肝脏疾病治疗的研究报道,初步验证其治疗的有效性及安全性,成为治疗肝病的一种新策略。本文就相关干细胞的分类、培养和移植方法、体内示踪和治疗肝脏疾病方面的最新研究进展进行论述。

关键词: 肝脏疾病, 干细胞, 治疗

Abstract: Stem cells have the ability to undergo self-renewal, proliferation and multi-lineage differentiation. As the most promising source of seed cells, the clinical applications of stem cells have become the focus of attention for years at home and abroad. There have been many reports about the applications of stem cells in treatment of liver diseases,which show the preliminary efficacy and safety. Stem cells therapies will emerge as a new treatment strategy for liver diseases. the progress about stem cells on the following aspects in this article was reviewed,such as the classification of stem cells,cell culture and transplantation,cell tracing in the body and the therapies for various liver diseases.

Key words: Stem cells, Liver diseases, Therapy

李珊珊, 洪丰综述, 陈煜审校. 干细胞治疗肝脏疾病研究进展^*[J]. 实用肝脏病杂志, 2018, 21(1): 145-148.

Li Shanshan, Hong Feng, Chen Yu. Stem cell therapy in liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 145-148.

参考文献

[1] Trounson A,Mcdonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell,2015,17（1）:11-22.
[2] Turner R,Lozoya O,Wang Y,et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology,2011,53（3）:1035-1045.
[3] Wang B,Zhao L,Fish M,et al. Self-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver. Nature,2015,524（7564）:180-185.
[4] 毕研贞,樊增,陈东风,等. 人肝源性干细胞腹腔移植不同时间对刀豆蛋白A诱导小鼠急性肝损伤保护作用.中华肝脏病杂志,2017,25（3）:201-207.
[5] Teratani T,Yamamoto H,Aoyagi K,et al. Direct hepatic fate specification from mouse embryonic stem cells. Hepatology,2005,41（4）:836-846.
[6] Kwon EM,Connelly JP,Hansen NF,et al. iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations. Proc Natl Acad Sci US A,2017,114（8）:1964-1969.
[7] Wang Y,Qin J,Wang S,et al. Conversion of human gastric epithelial cells to multipotent endodermal progenitors using defined small molecules. Cell Stem Cell,2016,19（4）:449-461.
[8] Kuo TK,Hung SP,Chuang CH,et al. Stem cell therapy for liver disease:parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology,2008,134（7）:2111-2113.
[9] Pan F,Liao N,Zheng Y,et al. Intrahepatic transplantation of adipose-derived stem cells attenuates the progression of non-alcoholic fatty liver disease in rats. Mol Med Rep,2015,12（3）:3725-3733.
[10] Garg V,Garg H,Khan A,et al. Granulocyte colony-stimulating factor mobilizes CD34+,cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology,2012,142（3）:505-512.
[11] Guo L,Zhou Y,Wang S,et al. Epigenetic changes of mesenchymal stem cells in three-dimensional （3D） spheroids. J Cell Mol Med,2014,18（10）:2009-2019.
[12] Li Y,Guo G,Li L,et al. Three-dimensional spheroid culture of human umbilical cord mesenchymal stem cells promotes cell yield and stemness maintenance. Cell Tissue Res,2015,360（2）:297-307.
[13] Chen Q,Utech S,Chen D,et al. Controlled assembly of heterotypic cells in a core-shell scaffold: organ in a droplet. Lab Chip,2016,16（8）:1346-1349.
[14] Nagamoto Y,Takayama K,Ohashi K,et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J Hepatol,2016,64（5）:1068-1075.
[15] Takebe T,Sekine K,Enomura M,et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature,2013,499（7459）:481-484.
[16] Wang Y,Cui CB,Yamauchi M,et al. Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds. Hepatology,2011,53（1）:293-305.
[17] Yan L,Han Y,He Y,et al. Cell tracing techniques in stem cell transplantation. Stem Cell Rev,2007,3（4）:265-269.
[18] Lei H,Nan X,Wang Z,et al. Stem cell labeling with superparamagnetic iron oxide nanoparticles using focused ultrasound and magnetic resonance imaging tracking. J Nanosci Nanotechnol,2015,15（4）:2605-2612.
[19] Herrera MB,Fonsato V,Bruno S,et al. Human liver stem cells improve liver injury in a model of fulminant liver failure.Hepatology,2013,57（1）:311-319.
[20] Shi D,Zhang J,Zhou Q,et al. Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs. Gut,2017,66（5）:955-964.
[21] Shi M,Zhang Z,Xu R,et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-
chronic liver failure patients. Stem Cells Transl Med,2012,1（10）:725-731.
[22] Suk KT,Yoon JH,Kim MY,et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis:Phase 2 trial. Hepatology,2016,64（6）:2185-2197.
[23] 于双杰,陈黎明,吕飒,等. 人脐带间充质干细胞治疗失代偿性乙型肝炎肝硬化的安全性与疗效. 中华肝脏病杂志,2016,24（1）:51-55.
[24] Sakisaka M,Haruta M,Komohara Y,et al. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci,2017,24（2）:109-119.
[25] Liao N,Pan F,Wang Y,et al. Adipose tissue-derived stem cells promote the reversion of non-alcoholic fatty liver disease: An in vivo study. Int J Mol Med,2016,37（5）:1389-1396.
[26] Wang L,Li J,Liu H,et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis.J Gastroenterol Hepatol,2013,28（S1）:85-92.
[27] Wang L,Han Q,Chen H,et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev,2014,23（20）:2482-2489.
[28] Chen Y,Chen S,Liu LY,et al. Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway. Immunol Lett,2014,162（2）:222-228.

干细胞治疗肝脏疾病研究进展^*

Stem cell therapy in liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[7]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[11]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[14]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[15]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.